Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
| ▸ | PRKCB | P05771 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | PRKCH | P24723 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5171764 | 1.00 | ACE2 (0.52) | ACE2OPRM1LMNASPHK1PRKD3 | |
| SCHEMBL5084030 | 1.00 | ACE2 (0.52) | ACE2OPRM1LMNASPHK1PRKD3 | |
| SCHEMBL5084234 | 1.00 | ACE2 (0.52) | ACE2OPRM1LMNASPHK1PRKD3 | |
| SCHEMBL5090674 | 1.00 | ACE2 (0.52) | ACE2OPRM1LMNASPHK1PRKD3 | |
| SCHEMBL5090259 | 0.98 | ACE2 (0.55) | ACE2OPRM1LMNASPHK1PRKD3 | |
| SCHEMBL11100412 | 0.98 | ACE2 (0.50) | ACE2OPRM1LMNASPHK1PRKD3 | |
| SCHEMBL5085878 | 0.98 | ACE2 (0.55) | ACE2OPRM1LMNASPHK1PRKD3 | |
| SCHEMBL11457428 | 0.98 | ACE2 (0.50) | ACE2OPRM1LMNASPHK1PRKD3 | |
| SCHEMBL5090227 | 0.98 | ACE2 (0.55) | ACE2OPRM1LMNASPHK1PRKD3 | |
| SCHEMBL5090100 | 0.98 | ACE2 (0.55) | ACE2OPRM1LMNASPHK1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592351-B2 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GRUENENTHAL GMBH (DE) | 2009-09-22 | — | — | US | claimed |
| US-20070099896-A1 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GRUENENTHAL GMBH (DE) | 2007-05-03 | — | — | US | claimed |
| US-7592351-B2 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GRUENENTHAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20070099896-A1 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GRUENENTHAL GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099896-A1 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GIPR, CHUK, ITPA | ACE2 231/4885OPRM1 1842/4885LMNA 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.